Overview

A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)

Status:
Active, not recruiting

Trial end date:
2026-03-29

Target enrollment:

Participant gender:

Summary

This study is designed to investigate belzutifan as a treatment for VHL disease associated RCC.

Phase:

Phase 2

Details

Lead Sponsor:

Peloton Therapeutics, Inc.